S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Autozone stock price is still in the rally zone
Salesforce stock got a boost. Is it growing off the Nvidia boom?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Autozone stock price is still in the rally zone
Salesforce stock got a boost. Is it growing off the Nvidia boom?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Autozone stock price is still in the rally zone
Salesforce stock got a boost. Is it growing off the Nvidia boom?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Autozone stock price is still in the rally zone
Salesforce stock got a boost. Is it growing off the Nvidia boom?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

$10.99
-0.04 (-0.36%)
(As of 02/27/2024 ET)
Today's Range
$10.89
$10.99
50-Day Range
$10.73
$12.28
52-Week Range
$10.39
$16.91
Volume
219,833 shs
Average Volume
239,271 shs
Market Capitalization
$19.89 billion
P/E Ratio
28.18
Dividend Yield
3.09%
Price Target
N/A

Astellas Pharma MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.57mentions of Astellas Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
100.00%
From $0.31 to $0.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.25 out of 5 stars


ALPMY stock logo

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

ALPMY Stock Price History

ALPMY Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Astellas Makes Announcement about Management Structure
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Astellas Pharma Announces Collaboration With Mass General Brigham
Astellas Pharma Inc. ADR
See More Headlines
Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
2/27/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
14,484
Year Founded
1923

Profitability

Net Income
$742 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.24 billion
Cash Flow
$1.36 per share
Book Value
$6.27 per share

Miscellaneous

Outstanding Shares
1,809,660,000
Free Float
N/A
Market Cap
$19.89 billion
Optionable
Not Optionable
Beta
0.34

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Naoki Okamura BSc (Age 62)
    President, CEO & Director
    Comp: $971.78k
  • Mr. Atsushi Kitamura
    Chief Financial Officer
  • Nobue Yasuda
    General Manager of Finance & Accounting Department
  • Mr. Yoshitsugu Shitaka Ph.D.
    Chief Scientific Officer & Senior Managing Executive Officer
  • Ms. Catherine B. Levitt
    General Counsel
  • Mr. Katsuyoshi Sugita (Age 57)
    Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
  • Mr. Stig Ogata
    Vice President of Corporate Communications
  • Ms. Collette Taylor (Age 61)
    Senior Vice President of Human Resources
  • Ms. Tatjana Dragovic
    Senior VP and Head of Ethics & Compliance
  • Mr. Nobuaki Tanaka
    President of Japan Commercial & Senior Corporate Executive

Should I Buy Astellas Pharma Stock? ALPMY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Astellas Pharma was last updated on Tuesday, February 20, 2024 at 9:55 PM.

Pros

Here are some ways that investors could benefit from investing in Astellas Pharma Inc.:

  • Astellas Pharma Inc. offers a diverse portfolio of pharmaceutical products, including XTANDI for prostate cancer, XOSPATA for relapsed or refractory acute myeloid leukemia, and PADCEV for metastatic urothelial cancer.
  • The company has ongoing research collaborations and partnership agreements, such as with Vivtex Corporation and Roche Diabetes Care Japan Co., Ltd., indicating a commitment to innovation and growth.
  • Despite the recent setback with the FDA declining to approve its gastric cancer drug, Astellas Pharma Inc. has not faced concerns related to its clinical data, which could indicate strong research and development capabilities.
  • Astellas Pharma Inc. has a long-standing history since its founding in 1923, providing a sense of stability and experience in the pharmaceutical industry.
  • Investors may find Astellas Pharma Inc. stock price attractive based on recent market trends and financial performance, offering a potential opportunity for capital appreciation.

Cons

Investors should be bearish about investing in Astellas Pharma Inc. for these reasons:

  • The recent FDA decision declining to approve Astellas' gastric cancer drug could impact the company's revenue projections and future growth potential in the oncology market.
  • Market volatility and regulatory challenges in the pharmaceutical industry may pose risks to Astellas Pharma Inc.'s stock performance and overall financial stability.
  • Competition from other pharmaceutical companies developing similar treatments could affect Astellas Pharma Inc.'s market share and pricing strategies.
  • Uncertainties surrounding global healthcare policies and regulations may introduce additional complexities for Astellas Pharma Inc.'s operations and market expansion efforts.
  • Investors should carefully monitor any updates on Astellas Pharma Inc.'s pipeline developments and regulatory interactions to assess potential risks and opportunities in the pharmaceutical sector.














ALPMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Astellas Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALPMY shares.
View ALPMY analyst ratings
or view top-rated stocks.

How have ALPMY shares performed in 2024?

Astellas Pharma's stock was trading at $11.90 at the start of the year. Since then, ALPMY shares have decreased by 7.6% and is now trading at $10.99.
View the best growth stocks for 2024 here
.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) released its quarterly earnings results on Monday, February, 5th. The company reported $0.12 earnings per share (EPS) for the quarter. The firm had revenue of $2.86 billion for the quarter. Astellas Pharma had a trailing twelve-month return on equity of 6.39% and a net margin of 0.08%.

Is Astellas Pharma a good dividend stock?

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.34 per share and currently has a dividend yield of 3.05%.

When did Astellas Pharma's stock split?

Shares of Astellas Pharma split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Astellas Pharma have any subsidiaries?
The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.
Read More
This page (OTCMKTS:ALPMY) was last updated on 2/28/2024 by MarketBeat.com Staff